In today’s Pharmaceutical Executive Daily learn how Novo Nordisk is restructuring leadership to enhance scientific and commercial alignment, ABL Bio secures a major multi-program partnership with Eli ...

Robert Armstrong There has been a wild and hectic series of M&A deals in the pharmaceuticals industry. We are now headed for ...

Neurona Therapeutics, a clinical-stage biotherapeutics company focused on advancing regenerative cell therapies for disorders of the nervous system, today announced the appointment of Eduardo ...

Tuesday, November 18, 2025 The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Microsoft ...

The next generation of weight loss drugs will hit the market in 2026. Eli Lilly and Novo Nordisk are racing to the finish ...

American Express is an advertising partner of Motley Fool Money. The Motley Fool has positions in and recommends Amazon, Peloton Interactive, and Pfizer. The Motley Fool recommends Coinbase Global and ...

The new generation of obesity medications are inducing greater weight loss than any prior pharmacotherapy. There is discussion now about how to support fat loss while protecting lean mass.“Lean mass ...

Alzheimer’s drug donanemab approved for use by drug regulator, likely to be available in India next year ...

The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current ...

United States President Donald Trump’s planned tariffs on pharmaceuticals have disrupted the industry. Here’s a timeline of ...

Vanda's Tradipitant Study Success Positions it as Key Adjunct in $50B+ Global GLP-1 Agonist Market WASHINGTON, Nov. 17, 2025 /PRNewswire/ -- Vanda Pharmaceuticals ...

By moving early, Novo Nordisk has got in with its price cut ahead of Lilly, whose deal involved dual GLP-1/CIP agonist ...